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Abstract
Aim: To evaluate the efficacy and safety of adjunct dapagliflozin therapy in patients
with type 1 diabetes (T1D).
Materials and Methods: DEPICT-1 and -2 were randomized, double-blind, parallel-
group, 24-week studies, with 28-week extension periods. Adults with T1D and
HbA1c 7.5%-10.5% were randomized (1:1:1) to receive dapagliflozin 5 mg, 10 mg or
placebo. The short- and long-term efficacy and safety of dapagliflozin were examined
in an exploratory pooled analysis of both studies.
Results: Efficacy analyses included 530, 529 and 532 and safety analysis included
548, 566 and 532 patients in the dapagliflozin 5 mg, 10 mg and placebo groups, respec-
tively. Baseline characteristics were similar between treatment groups. At week 24, reduc-
tions were seen with dapagliflozin 5 and 10 mg compared with placebo in HbA1c
(−0.40%, −0.43% vs. 0.00%) and body weight (−2.45, −2.91 vs. 0.11 kg). HbA1c and body
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weight reductions versus placebo were also seen after 52 weeks of treatment. There was
no imbalance in occurrence of severe hypoglycaemic events between groups. The propor-
tion of patients experiencing definite diabetic ketoacidosis (DKA) was higher with
dapagliflozin 5 mg (4.0%) and 10 mg (3.5%) compared with placebo (1.1%) over 52 weeks;
most events were of mild or moderate severity, and all resolved with treatment.
Conclusions: Over 52 weeks, dapagliflozin provided glycaemic and weight benefits,
with no increased frequency of severe hypoglycaemia compared with placebo. More
DKA events were reported with dapagliflozin than placebo, highlighting the impor-
tance of appropriate patient selection, education and risk-mitigation strategies.
K E YWORD S
dapagliflozin, DEPICT, DKA, insulin adjunct, long-term data, severe hypoglycaemia, SGLT-2
inhibitor, T1D
1 | INTRODUCTION
Patients with type 1 diabetes (T1D) require life-long insulin therapy to
maintain glycaemic control.1 However, the majority of the affected
population fail to achieve glycaemic targets, with only 30% of adults
with T1D achieving HbA1c of less than 7.0%.2 There is a need for
treatments acting through insulin-independent pathways that can be
used as add-on therapy in patients with T1D to improve glycaemic
control without causing hypoglycaemia and weight gain.
DEPICT-1 and -2 were phase III, randomized, double-blind,
parallel-group, 24-week studies, with 28-week extension periods,
investigating the efficacy and safety of dapagliflozin used as an
adjunct to adjustable insulin therapy in adult patients with T1D
and uncontrolled hyperglycaemia.3–5 Based on the results of the
DEPICT studies, the sodium-glucose co-transporter-2 (SGLT-2)
inhibitor dapagliflozin (5 mg dose) has been approved by the
European Medicines Agency for use as an adjunct to adjustable
insulin in patients with T1D and body mass index (BMI) of 27 kg/
m2 or higher.6 In Japan, dapagliflozin 5 and 10 mg doses have been
approved for use as an adjunct to insulin therapy for patients with
T1D, regardless of BMI.7,8
Results from the DEPICT studies showed that adjunct
dapagliflozin therapy resulted in improved HbA1c and reduced body
weight, without an increase in the risk of hypoglycaemia; however,
there is a lack of reported findings on whether the benefit/risk bal-
ance of dapagliflozin treatment differs among patients with different
characteristics, for example, high or very high HbA1c at baseline, or
the method of insulin administration.
The aim of this analysis was to report the safety and efficacy of
adjunct dapagliflozin therapy in a pooled population from the
DEPICT-1 and -2 studies. In addition, we aimed to explore whether
the efficacy and safety of dapagliflozin treatment differs between
subgroups of patients according to baseline HbA1c (<75 mmol/mol
[<9.0%] or ≥75 mmol/mol [≥9.0%]) or method of insulin administra-
tion (continuous subcutaneous insulin infusion [CSII] or multiple daily
injections [MDI]).
2 | METHODS
2.1 | Study design
This was a pooled analysis of the DEPICT-1 (NCT02268214) and DEPICT-2
(NCT02460978) studies. Study designs for DEPICT-1 and DEPICT-2 have
been described previously.3–5 Both studies included an 8-week lead-in
period to optimize diabetes management; a 24-week, double-blind treat-
ment period (short-term period); a 28-week subject- and site-blinded exten-
sion (long-term period); and a 4-week follow-up period.
2.2 | Participants
In brief, this pooled analysis included participants aged 18-75 years with
inadequately controlled T1D (HbA1c 7.7%-11.0% [61-97 mmol/mol] at
screening/enrolment; 7.5%-10.5% [58-91 mmol/mol] at randomization),
BMI 18.5 kg/m2 or higher, and C-peptide less than 0.7 ng/mL
(<0.23 nmol/L). Participants were required to have been taking insulin
for 12 months or longer prior to screening, without changing the method
of administration for 3 months or longer, and with a total insulin dose of
0.3 U/kg/day or more, and to be receiving CSII, or three or more injec-
tions of insulin/day if following a MDI regimen. Patients were excluded if
they previously used any SGLT-2 inhibitor, had type 2 diabetes (T2D),
maturity onset diabetes of the young, pancreatic disorders resulting in
decreased β-cell capacity, diabetes insipidus, diabetic ketoacidosis (DKA)
requiring medical intervention within 1 month before screening, or had
been hospitalized for hyperglycaemia or hypoglycaemia within 1 month.
A detailed list of inclusion and exclusion criteria for patients participating
in the DEPICT trials has been published previously.3–5
2.3 | Procedures
Eligible patients were randomized (1:1:1) to receive dapagliflozin
5 mg, dapagliflozin 10 mg or placebo in addition to insulin, with
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randomization stratified by use of continuous glucose monitoring
(CGM), method of insulin administration and baseline HbA1c.
Throughout the study, insulin dose could be adjusted according to
self-monitored blood-glucose readings, local guidance and individual
circumstances. Basal and bolus insulin doses were recommended to
be reduced by up to 20% on day 1, before attempting to titrate back
to baseline levels. Change in mode of insulin administration was not
allowed except temporarily, for up to 2 weeks, in certain circum-
stances, such as when a patient using an insulin pump needed a
replacement pump and the temporary use of MDI was allowed. Up to
week 24, each insulin dose was recorded every day during select
2-week collection periods. At other times, and from week 24 and




Efficacy outcomes for this pooled analysis were mean change from
baseline in HbA1c (primary efficacy outcome for the DEPICT-1 and
DEPICT-2 studies at week 24), mean % changes from baseline in total
daily insulin dose (TDID) and body weight, mean change from baseline
in seated systolic blood pressure (SBP) in patients with hypertension
at baseline (SBP ≥ 140 mmHg and/or seated diastolic blood
pressure ≥ 90 mmHg), and proportion of patients achieving an HbA1c
reduction of 0.5% or higher without severe hypoglycaemia. Efficacy
findings were reported for the short- and long-term treatment
periods. Data were also reported for the 30-day post-treatment
follow-up visit, if available.
Subgroup analyses were conducted to assess the difference ver-
sus placebo in HbA1c, TDID and body weight in subgroups of patients
with baseline HbA1c less than 75 mmol/mol (<9.0%) or 75 mmol/mol
or higher (≥9.0%), or according to the method of insulin administration
(CSII or MDI). Placebo-adjusted differences for HbA1c and body
weight for the subgroup analyses were reported for week 24 and 52.
Difference versus placebo for TDID for the subgroups was only
reported for week 24, as between week 24 and 52, patients only
recorded the midpoint for basal and bolus insulin dose each week and
comparative analysis was not conducted for this period.
2.4.2 | Safety
Safety assessments, including adverse events (AEs) and serious AEs
(SAEs), were monitored throughout the long-term study period,
including up to the week 56 follow-up visit, and are reported for the
pooled population as well as for the subgroups. AEs of special interest,
including hypoglycaemia, DKA, genital infections, urinary tract infec-
tions, fractures and cardiovascular AEs, were also recorded.
Details of assessing hypoglycaemia and DKA have been described
previously.3–5 Hypoglycaemic events were defined according to the
American Diabetes Association (ADA) classification criteria.9,10 Severe
hypoglycaemia was defined as an event resulting in unconsciousness
caused by hypoglycaemia or an event requiring the assistance of
another person to administer carbohydrate, glucagon, or to take other
corrective actions to promote neurological recovery.9
Patients were advised on identifying potential DKA events, and
were provided with blood ketone meters with instructions for their
use to record ketone levels. Potential DKA events were identified
based on investigator review of home ketone meter readings, review
of symptoms and diagnoses, and from queries according to predefined
terms in the Standardized Medical Dictionary for Regulatory Activi-
ties. An independent DKA Adjudication Committee adjudicated all
reported DKA events. Criteria for definite DKA included acidosis diag-
nosed by low blood pH (<7.3) and/or decreased serum bicarbonate
levels (≤18 mEq/L). Symptoms/signs listed in the ADA consensus
statement on the diagnosis of DKA were also assessed.11 There were
no adjudication criteria for possible and improbable DKA events.
2.5 | Statistical analysis
Data from patients in both DEPICT studies were pooled for this analy-
sis. All efficacy analyses, including analyses for the subgroups, were
performed using the full analysis set (defined as all correctly random-
ized patients who received ≥1 dose of the study medication during
the 24-week period and who had baseline and any postbaseline
assessments). In DEPICT-1, 55 patients were incorrectly and non-
randomly allocated by the interactive voice-response system to the
dapagliflozin treatment arms because of a randomization system error.
These patients are included in the safety analysis set based on the
treatment received (18 patients received ≥1 dose of dapagliflozin
5 mg and 37 subjects received ≥1 dose of dapagliflozin 10 mg), but
they were removed from the full analysis set for the efficacy analyses.
Change and % change from baseline for the overall population
and difference versus placebo for the subgroup analyses were
assessed using a longitudinal repeated measures analysis. Independent
variables for the overall population analyses were baseline value,
treatment, study, study week, randomization stratification factor, the
interaction between study week and treatment, and the interaction
between study week and baseline value. Independent variables for
the subgroup analyses were baseline value, treatment, study, study
week, randomization stratification factor, the interaction between
study week and treatment, the interaction between study week and
baseline value, subgroup, the interaction between treatment and sub-
group, the interaction between study week and subgroup, and the
interaction between treatment, study week and subgroup.
Logistic regression was used to calculate the proportion of
patients achieving an HbA1c reduction of 0.5% or higher without
severe hypoglycaemia with adjustment for the randomization stratifi-
cation factor and baseline HbA1c values. For missing data, the last
observation carried forward (LOCF) method was used. Odds ratios
(OR), based on logistic regression, for other endpoints and their asso-
ciated 95% confidence intervals (CI), were determined for
PHILLIP ET AL. 551
dapagliflozin (both doses) versus placebo. No P-values were calculated
for treatment group comparisons, as all efficacy analyses for the
pooled dataset were exploratory.
No formal analysis was conducted to compare TDID between the
groups beyond week 24 because different methods were used to
record the data.
Safety outcomes were summarized descriptively and assessed
using the safety analysis set that included all patients receiving one or
more doses of study medication during the short-term, double-blind
treatment period. Safety analyses were performed over 52 weeks,
plus the 30-day follow-up period.
3 | RESULTS
3.1 | Patients
Of the 1646 patients randomized at the initiation of the short-term
periods of the DEPICT-1 (n = 833) and DEPICT-2 (n = 813) studies,
1464 patients (88.9%) entered the long-term extensions (DEPICT-1:
n = 747; DEPICT-2: n = 717). The full analysis set for this pooled pop-
ulation included 530, 529 and 532 patients in the dapagliflozin 5 mg,
10 mg and placebo groups, respectively, and the safety analysis set













































































DAPA 10 mg + insulin (n = 529) Placebo + insulin (n = 532)DAPA 5 mg + insulin (n = 530)
523 514 512 505 487 481 466 458 436 429DAPA 10 mg 456
521 517 504 491 483 477 464 457 429 436DAPA 5 mg 463






Difference vs. placebo (95% CI) at week 24:
DAPA 5 mg: –0.40% (–0.48%, –0.31%)
DAPA 10 mg: –0.43% (–0.52%, –0.34%)
Difference vs. placebo (95% CI) at week 52:
DAPA 5 mg: –0.26% (–0.37%, –0.16%)
DAPA 10 mg: –0.30% (–0.41%, –0.20%)
Difference vs. placebo (95% CI) at week 24:
DAPA 5 mg: –3.11% (–3.61%, –2.62%)
DAPA 10 mg: –3.71% (–4.20%, –3.22%)
Difference vs. placebo (95% CI) at week 52:
DAPA 5 mg: –3.66% (–4.24%, –3.07%)
DAPA 10 mg: –4.66% (–5.24%, –4.08%)
Difference vs. placebo (95% CI) at week 24:
DAPA 5 mg: –2.86 mmHg (–6.35, –0.63)
DAPA 10 mg: –2.04 mmHg (–5.59, –1.51)
Difference vs. placebo (95% CI) at week 52:
DAPA 5 mg: –3.72 mmHg (–7.76, –0.31)
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Difference vs. placebo (95% CI) at week 24
DAPA 5 mg: –9.57 (–12.01, –7.07)
DAPA 10 mg: –11.75 (–14.13, –9.30)
Mean (SD) total insulin dose at baseline (IU)
DAPA 5 mg: 60.2 (36.8)











































DAPA 10 mg + insulin (n = 529) Placebo + insulin (n = 532)DAPA 5 mg + insulin (n = 530)
DAPA 10 mg + insulin (n = 529) Placebo + insulin (n = 532)DAPA 5 mg + insulin (n = 530) DAPA 10 mg + insulin (n = 70) Placebo + insulin (n = 85)DAPA 5 mg + insulin (n = 75)
F IGURE 1 A, adjusted mean (SE) change from baseline to week 52 in HbA1c, B, adjusted mean (SE) % change from baseline to week 52 in
total daily insulin dose, C, adjusted mean (SE) % change from baseline to week 52 in body weight and D, adjusted mean (SE) change from baseline
to week 52 in SBP (for patients with hypertension at baseline) (full analysis set). For HbA1c, body weight and SBP, adjusted mean change or %
change is shown up to week 52. For insulin dose, up to week 24 insulin was recorded daily at set times, but from week 24 to 52 patients
recorded the midpoint for basal and bolus insulin dose for each week. Therefore, B represents the mean % change over time (descriptive only); for
HbA1c, body weight and SBP, values at week 56 (post-treatment follow-up visit) are mean change; for HbA1c and SBP, mixed model: change
from baseline = baseline treatment study week stratum week*treatment week*baseline; for insulin dose and body weight, mixed model: log(post)
– log (baseline) = log(baseline) treatment study week stratum week*treatment week*log(baseline); stratum includes one term for each
combination of all stratification factors. DAPA, dapagliflozin; SBP, systolic blood pressure
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85.0% and 81.6% of patients in the dapagliflozin 5 mg, 10 mg and pla-
cebo groups, respectively, completed the 52-week treatment period.
The main reasons for study discontinuation were occurrence of AEs
(1.9%) and patients requesting to discontinue (1.0%). Baseline charac-
teristics were similar between treatment groups (Table S1).
3.2 | Efficacy outcomes
Reductions in HbA1c from baseline were observed at week 24 and
52 with both dapagliflozin doses, with minimal changes in the placebo
group (Figure 1A). Adjusted mean (SE) change in HbA1c from baseline
was −0.40 (0.03) % for dapagliflozin 5 mg, −0.43 (0.03) % for
dapagliflozin 10 mg and 0.00 (0.04) % for placebo at week 24, and
−0.20 (0.04) % for dapagliflozin 5 mg, −0.23 (0.04) % for dapagliflozin
10 mg and 0.07 (0.04) % for placebo at week 52. There were, in total,
154 patients (47 in the dapagliflozin 5 mg group, 47 in the
dapagliflozin 10 mg group and 60 in the placebo group) that were
missing HbA1c data at week 24 and there were 286 patients (86 in
the dapagliflozin 5 mg group, 92 in the dapagliflozin 10 mg group and
108 in the placebo group) that were missing HbA1c data at week 52;
LOCF was utilized in these patients.
TDID decreased from baseline by week 2 with dapagliflozin 5 and
10 mg, and remained lower than placebo in both dapagliflozin groups over
the 52 weeks of treatment (Figure 1B). Mean (SD) TDID at baseline for
patients included in this analysis was 60.2 (36.8) IU with dapagliflozin
5 mg, 59.3 (28.2) IU with dapagliflozin 10 mg and 59.7 (27.5) IU with pla-
cebo (Figure 1B). Adjusted mean (SE) % change in TDID from baseline was
−8.30 (0.97) % for dapagliflozin 5 mg, −10.51 (0.96) % for dapagliflozin
10 mg and 1.40 (1.09) % for placebo at week 24. Basal and bolus daily
insulin doses were similarly reduced at week 24 compared with placebo in
patients who received either dose of dapagliflozin. Adjusted mean (SE) %
change from baseline to week 24 in basal insulin was −11.50 (0.97) % for
dapagliflozin 5 mg, −15.33 (0.94) % for dapagliflozin 10 mg and 0.18 (1.12)
% for placebo (difference [95% CI] vs. placebo: dapagliflozin 5 mg,
−11.65% [−14.15, −9.08]; dapagliflozin 10 mg, −15.48% [−17.87,
−13.02]). Adjusted mean (SE) % change from baseline to week 24 in bolus
insulin was −12.83 (1.45) % with dapagliflozin 5 mg, −13.11 (1.46) % with
dapagliflozin 10 mg and −3.46 (1.64) % with placebo (difference [95% CI]
vs. placebo: dapagliflozin 5 mg, −9.70% [−13.54, −5.69]; dapagliflozin
10 mg, −9.99% [−13.83, −5.98]).
Both dapagliflozin doses had greater reductions in body weight at
week 24 compared with placebo; this was also seen after 52 weeks of
treatment, with further reductions in body weight seen with
dapagliflozin compared with placebo (Figures 1C, S1). Adjusted mean
(SE) % change from baseline in body weight was −3.10 (0.18) %
(−2.45 [0.14] kg) for dapagliflozin 5 mg, −3.70 (0.18) % (−2.91 [0.14]
kg) for dapagliflozin 10 mg and 0.02 (0.19) % (0.11 [0.14] kg) for pla-
cebo at week 24 and −3.22 (0.21) % (−2.57 [0.18] kg) for dapagliflozin
5 mg, −4.23 (0.21) % (−3.34 [0.18] kg) for dapagliflozin 10 mg and
0.45 (0.22) % (0.44 [0.18] kg) for placebo at week 52.
At baseline, 230 patients had hypertension (defined as SBP
≥ 140 mmHg and/or seated diastolic blood pressure ≥ 90 mmHg;
dapagliflozin 5 mg: n = 75; dapagliflozin 10 mg: n = 70; placebo:
n = 85), with mean (SD) baseline SBP values in these patients of
145.52 (9.66) mmHg in the dapagliflozin 5 mg group, 145.81 (9.60)
mmHg in the dapagliflozin 10 mg group and 144.11 (10.85) mmHg in
the placebo group (Figure 1D). Adjusted mean (SE) change from base-
line in SBP was −13.30 (1.40) mmHg for dapagliflozin 5 mg,
−12.47 (1.43) mmHg for dapagliflozin 10 mg and − 10.44 (1.36)
mmHg for placebo at week 24 and −12.39 (1.58) mmHg for
dapagliflozin 5 mg, −12.91 (1.67) mmHg for dapagliflozin 10 mg and
−8.67 (1.54) mmHg for placebo at week 52.
The proportion of patients achieving an HbA1c reduction of 0.5%
or higher without severe hypoglycaemia was greater with
dapagliflozin 5 and 10 mg than with placebo after 24 and 52 weeks of
treatment (Figure S2).
Overall, similar trends were seen in the subgroup analyses in
patients with baseline HbA1c of less than 75 mmol/mol (<9.0%)
or 75 mmol/mol or higher (≥9.0%) and those using MDI or CSII. At
week 24, placebo-adjusted differences from baseline for HbA1c, body
weight and TDID were comparable between the overall pooled popu-
lation and the subgroups of patients with different baseline HbA1c
(Figure 2), as well as MDI and CSII users (Figure 3). Differences versus
placebo in HbA1c and body weight were also observed after
52 weeks of treatment in the subgroups.
3.3 | Safety outcomes
Over the study period (52 weeks plus 30-day follow-up), one or more AE
was reported for 79.9%, 77.9% and 74.1% of patients in the dapagliflozin
5 mg, 10 mg and placebo groups, respectively, and one or more SAE was
reported in 12.6%, 10.4% and 8.6% of patients, respectively (Table 1). More
genital infections were reported for dapagliflozin 5 and 10 mg than with pla-
cebo over 24 and 52 weeks of treatment. The proportion of patients
reporting AEs and SAEs over the entire study period was comparable
between the overall pooled population and the subgroups of patients with
baseline HbA1c of less than 75 mmol/mol (<9.0%) or 75 mmol/mol or higher
(≥9.0%) and those receiving insulin via CSII or MDI (Tables S2 and S3).
The total number of hypoglycaemic and severe hypoglycaemic
events were similar in all treatment groups over 24 and 52 weeks
(Table S4). Hypoglycaemia events, including severe hypoglycaemia,
were also comparable between the overall populations and baseline
HbA1c subgroups or MDI versus CSII users (Tables S2 and S3).
Over 52 weeks, more patients in the dapagliflozin groups than in
the placebo group had events adjudicated as definite DKA (Table 2).
Of the definite DKA events, 36.7% (18/49) were adjudicated as mild,
40.8% (20/49) as moderate and 22.4% (11/49) as severe. There was
also a higher number of euglycaemic DKA events in the dapagliflozin
group compared with the placebo group. The identified primary cau-
ses of DKA over the 52-week period were missed insulin dose (34.8%
[8/23] with dapagliflozin 5 mg, 25.0% [5/20] with dapagliflozin 10 mg
and 16.7% [1/6] with placebo), insulin pump failure (17.4% [4/23]
with dapagliflozin 5 mg, 25.0% [5/20] with dapagliflozin 10 mg and
33.3% [2/6] with placebo) and severe illness (4.3% [1/23] with
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dapagliflozin 5 mg, 5.0% [1/20] with dapagliflozin 5 mg and 0% with
placebo). The cause of definite DKA was ‘other’ or ‘not identified’ in
43.4% (10/23) of cases with dapagliflozin 5 mg, 45% (9/20) with
dapagliflozin 10 mg and 50% (3/6) with placebo. All DKA events were
resolved with treatment.
The incidence of events adjudicated as definite DKA throughout
the study period was comparable between baseline HbA1c subgroups
for patients treated with dapagliflozin (Table S2). There were more
events in patients treated with dapagliflozin than in those treated with
placebo. Overall, there was a greater proportion of patients experienc-
ing DKA events in the dapagliflozin groups and the placebo group
when administering insulin via CSII compared with MDI (Table S3).
4 | DISCUSSION
The DEPICT-1 and DEPICT-2 studies had near-identical designs and
showed consistent results, which allowed a pooled analysis. The
analysis of this large pooled dataset investigated the use of adjunct
SGLT-2 therapy for the management of T1D. In this geographically
diverse population of people with T1D, dapagliflozin provided
glycaemic and weight benefits, along with reductions in insulin dose
over 52 weeks. Here, we also provide evidence that the safety and
efficacy of adjunct dapagliflozin therapy was consistent across base-
line HbA1c subgroups and by the method of insulin administration.
Results of this pooled analysis showed a clinically relevant
decrease in HbA1c with adjunct dapagliflozin therapy at week
24, which was also seen, although to a lesser extent, at week 52. In
addition, the decrease in HbA1c was observed without an increase in
the risk of hypoglycaemia or weight gain. Indeed, body weight had
begun to decrease with dapagliflozin treatment by week 2 and
remained lower than in the placebo group throughout the treatment
period. Furthermore, reduction in HbA1c was seen despite reductions
in TDID. With intensive insulin therapy being a major cause of weight
gain in T1D,12 the reduction in TDID without compromising blood glu-
cose control is a desirable outcome in T1D management.
F IGURE 2 Difference versus placebo with dapagliflozin 5 mg and 10 mg for A, change from baseline in HbA1c at week 24 and 52, B, %
change from baseline in body weight at week 24 and 52, C, % change from baseline in total daily insulin dose at week 24 in subgroups of patients
with baseline HbA1c < 75 mmol/mol (<9.0%) or ≥75 mmol/mol (≥9.0%). The mixed model included terms for baseline, treatment, study, week,
stratum, week*treatment, week*baseline, subgroup, treatment*subgroup, week*subgroup and treatment*week*subgroup. Stratum includes one
term for each combination of the three stratification factors on baseline HbA1c, use of personal continuous glucose monitoring system and
methods of insulin administration. CI, confidence interval; DAPA, dapagliflozin; PBO, placebo; TDID, total daily insulin dose
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Reduction in body weight observed in the DEPICT studies may
be caused by caloric loss from SGLT-2–mediated glycosuria, as is the
case in T2D.13 The extent of any additional contribution of insulin
dose reduction to weight loss is not clear. Importantly, weight loss has
been associated with reduced cardiovascular co-morbidity in patients
with T1D,14 therefore, the initiation of a treatment that has a poten-
tial to reduce body weight may also contribute to a reduction in the
risk of cardiovascular disease.
The subgroup analyses according to the baseline HbA1c and
method of insulin administration showed comparable efficacy results
with the overall DEPICT population. In studies in patients with T2D,
the glucose-lowering effect of SGLT-2 inhibitors was greater in sub-
jects with high HbA1c levels compared with those with low HbA1c
levels,15,16 which was not observed in the patients with T1D investi-
gated in the DEPICT trials. One possible reason for this could be that
the patients with T1D in the DEPICT studies had insulin administered
via MDI or CSII, and the dose could be freely adjusted throughout the
day as needed. Compared with patients with T1D, patients with T2D
receiving insulin therapy usually receive more stable doses of insulin,
and in many cases do not use bolus insulin. This possibility to freely
adjust insulin throughout the day in the DEPICT studies may have
masked the full glycaemic potential of dapagliflozin in this population.
Improved glycaemic control has been associated with reduced
microvascular and macrovascular complications.17–19 Dapagliflozin
has been shown to reduce hypertension, arterial stiffness and the risk
of diabetic retinopathy in patients with T2D, all of which are common
complications of T1D related to uncontrolled hyperglycaemia.20–23
While there was a trend towards greater reductions in SBP seen in
this analysis with dapagliflozin compared with placebo in patients with
hypertension at baseline, no significant differences in SBP were
F IGURE 3 Difference versus placebo with dapagliflozin 5 and 10 mg for A, change from baseline in HbA1c at week 24 and 52, B, % change
from baseline in body weight at week 24 and 52, C, % change from baseline in total daily insulin dose at week 24 in subgroups of patients
receiving insulin either via continuous subcutaneous insulin infusion (CSII) or multiple daily injections (MDI). The mixed model included terms for
baseline, treatment, study, week, stratum, week*treatment, week*baseline, subgroup, treatment*subgroup, week*subgroup and
treatment*week*subgroup. Stratum includes one term for each combination of the three stratification factors on baseline HbA1c, use of personal
continuous glucose monitoring system and methods of insulin administration. CI, confidence interval; DAPA, dapagliflozin; PBO, placebo; TDID,
total daily insulin dose
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observed across the study groups. The immediate reductions in SBP
observed here may be a result of regression to the mean, as hyperten-
sion was defined as SBP of 140 mmHg or higher and/or seated dia-
stolic blood pressure of 90 mmHg or higher at baseline, rather than a
history of diagnosis of hypertension.
The safety profile of dapagliflozin in this pooled analysis of
patients with T1D was generally consistent with that seen with
dapagliflozin in patients with T2D.24,25 There was, however, a 3-fold
increase in DKA reported with dapagliflozin compared with placebo.
The DKA incidence was within the range reported for the general
T1D population26 and has also been seen in studies with other
SGLT-2 inhibitors.27,28 The underlying causes of the increased DKA
risk with SGLT-2 treatment compared with placebo are not well
known,29 but there is some evidence that this might be associated
with a failure to recognize early metabolic decompensation.30 It has
been shown that during insulin suspension, patients being treated
TABLE 1 Safety outcomesa for the DEPICT pooled population
Week 24 (short-term period) Week 52 (short-term + long-term period)
DAPA
5 mg (N = 548)
DAPA




5 mg (N = 548)
DAPA




≥1 AE 384 (70.1) 388 (68.6) 332 (62.4) 438 (79.9) 441 (77.9) 394 (74.1)
≥1 AE related to study drug 157 (28.6) 153 (27.0) 63 (11.8) 181 (33.0) 180 (31.8) 88 (16.5)
AE leading to study discontinuation 23 (4.2) 20 (3.5) 20 (3.8) 35 (6.4) 30 (5.3) 27 (5.1)
AE of special interestb
Adjudicated CV event 2 (0.4) 5 (0.9) 2 (0.4) 2 (0.4) 5 (0.9) 4 (0.8)
Events of renal function 6 (1.1) 2 (0.4) 0 7 (1.3) 3 (0.5) 4 (0.8)
Fracture 8 (1.5) 6 (1.1) 5 (0.9) 12 (2.2) 11 (1.9) 12 (2.3)
Urinary tract infection 37 (6.8) 21 (3.7) 25 (4.7) 57 (10.4) 30 (5.3) 39 (7.3)
Malec 2 (0.8) 2 (0.7) 3 (1.2) 4 (1.7) 4 (1.5) 4 (1.6)
Femaled 35 (11.3) 19 (6.5) 22 (7.8) 53 (17.0) 26 (8.9) 35 (12.5)
Genital infection 61 (11.1) 54 (9.5) 12 (2.3) 73 (13.3) 68 (12.0) 18 (3.4)
Malec 12 (5.1) 12 (4.4) 0 13 (5.5) 17 (6.2) 0
Femaled 49 (15.8) 42 (14.3) 12 (4.3) 60 (19.3) 51 (17.4) 18 (6.4)
SAEs
≥1 SAE 37 (6.8) 31 (5.5) 20 (3.8) 69 (12.6) 59 (10.4) 46 (8.6)
≥1 SAE related to study drug 18 (3.3) 12 (2.1) 3 (0.6) 23 (4.2) 20 (3.5) 6 (1.1)
SAE leading to study
discontinuation
15 (2.7) 7 (1.2) 6 (1.1) 22 (4.0) 13 (2.3) 9 (1.7)
Hypoglycaemia
≥1 SAE of hypoglycaemia 6 (1.1) 2 (0.4) 2 (0.4) 8 (1.5) 5 (0.9) 5 (0.9)
Hypoglycaemia leading to study
discontinuation
3 (0.5) 0 1 (0.2) 3 (0.5) 1 (0.2) 2 (0.4)
Ketone-related eventse
≥1 ketone-related SAE 14 (2.6) 11 (1.9) 2 (0.4) 28 (5.1) 20 (3.5) 4 (0.8)
Ketone related SAE leading to
study discontinuation
9 (1.6) 7 (1.2) 0 14 (2.6) 11 (1.9) 0
Deathf 0 0 1 (0.2) 1 (0.2) 0 1 (0.2)
Abbreviations: AE, adverse event; CV, cardiovascular; DAPA, dapagliflozin; DKA, diabetic ketoacidosis; MedDRA, Medical Dictionary for Regulatory
Activities; SAE, serious adverse event.
a24-week data include non-SAEs seen from day 1 of treatment up to and including 4 days after the last dose in the short-term period; 52-week data also
include events up to and including 30 days after the last dose in the short- +long-term period.
bBased on a list of prespecified list of MedDRA preferred terms.
cDenominator is the number of male patients in the DAPA 5 mg (n = 237), DAPA 10 mg (n = 273) and placebo (n = 251) groups.
dDenominator is the number of female patients in the DAPA 5 mg (n = 311), DAPA 10 mg (n = 293) and placebo (n = 281) groups.
ePreferred terms for ketone-related events were acetonaemia, acidosis, ketoacidosis, ketosis, metabolic acidosis, uraemic acidosis, DKA, diabetic metabolic
decompensation, blood ketone body, blood ketone body increased, urine ketone body present, blood ketone body present, urine ketone body, diabetic
ketoacidotic hyperglycaemic coma, ketonuria, diabetic ketosis, euglycaemic DKA.
fOne death in the DAPA 5 mg group was attributed to an SAE that was not related to the study treatment.
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with SGLT-2 inhibitors have a much more gradual rate of increase in
plasma glucose levels and reach a plateau, which may result in delayed
recognition of metabolic decompensation.30 Indeed, euglycaemic
DKA was more common in those receiving dapagliflozin treatments.
This suggests that clinicians and patients should not depend solely on
the elevation in plasma glucose levels for the detection of DKA, but
should also include the monitoring of blood or urine ketones and on
whether there are any other symptoms, such as nausea, vomiting or
dehydration.31
The subgroup analyses of the DEPICT studies showed that there
were more DKA events observed in those using CSII in both of the
dapagliflozin groups and the placebo group compared with those
using MDI. This was also found in a meta-analysis of randomized con-
trolled trials, where DKA was generally more common in those having
CSII as the mode of insulin administration, regardless of the use of
SGLT-2 inhibitors.32 Hence, the risk ratio is not higher in users of CSII
for dapagliflozin versus placebo, but may only reflect DKA being more
common in patients who use CSII versus MDI.
It should also be noted that at the time the studies were con-
ducted, less was known regarding the risk of DKA, its management
and appropriate patient education, than has since then become avail-
able. Learnings from these studies include the need for patient and
physician education about possible risk factors for DKA, risk-
reduction strategies and management as well as reporting of DKA
TABLE 2 Summary of DKA eventsa for the DEPICT pooled population
Week 24 (short-term period) Week 52 (short-term + long-term period)
DAPA













Patients with adjudicated definite
DKA, n (%)
11 (2.0) 11 (1.9) 3 (0.6) 22 (4.0) 20 (3.5) 6 (1.1)
Events sent for adjudication, n 54 41 28 81 76 40
Number of events of definite DKA, n 11 11 3 23 20 6
Incidence rate, per 100 patient-years 4.55 4.36 1.29 4.62 3.85 1.27
Severity of event as adjudicated, n
Mild 5 4 1 9 6 3
Moderate 4 4 1 8 10 2
Severe 2 3 1 6 4 1
Number of events of euglycaemic
DKAb, n
2 3 0 6 7 1
Primary cause for definite DKA events, n
Insulin pump failure 3 3 1 4 5 2
Missed insulin dose 3 4 1 8 5 1
Severe illness 0 0 0 1 1 0
Not identified 5 0 0 7 3 1
Other 0 4 1 3 6 2
Mean total insulin dose reduction
compared to baseline for week before
definite DKA events, %
−13.94 −23.29 −7.79 −3.57 −21.05 −10.14
Mean total insulin dose reduction
compared with baseline at end of
treatment period in patients with
definite DKA events, %
−13.80 −22.39 30.76 −12.08 −20.43 5.07
Events adjudicated as not DKA
Patients with possible DKA, n (%) 11 (2.0) 11 (1.9) 3 (0.6) 16 (2.9) 13 (2.3) 4 (0.8)
Number of events of possible DKA, n 14 12 5 22 14 6
Patients with improbable DKA, n (%) 16 (2.9) 12 (2.1) 10 (1.9) 19 (3.5) 21 (3.7) 12 (2.3)
Number of events of improbable
DKA, n
29 18 20 36 42 28
Abbreviations: DAPA, dapagliflozin; DKA, diabetic ketoacidosis.
a24-week data include non-SAEs seen from day 1 of treatment up to and including 4 days after the last dose in the short-term period; 52-week data also
include events up to and including 30 days after the last dose in the short- +long-term period.
bEuglycaemic DKA was defined as having a measured glucose below 250 mg/dL closest to the time of the highest beta-hydroxybutyrate value.
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events, which should all be implemented before initiating adjunct
SGLT-2 inhibitor therapy in patients with T1D.33 Selection of appro-
priate patients for adjunct SGLT-2 inhibitor therapy should be based
on patient lifestyle (e.g. treatment adherence, diet, alcohol consump-
tion) and regular monitoring of ketones. It is important that patients
taking these agents are educated to respond appropriately to elevated
ketone levels to minimize the risk of DKA.34–36 Clinicians and patients
should also be aware that DKA may present in those receiving adjunct
SGLT-2 inhibitor therapy without overtly elevated glucose levels
(euglycaemic DKA), which may delay diagnosis and treatment if not
promptly recognized.34
The DEPICT studies, and this pooled analysis, have some limi-
tations. During both studies, insulin was recorded daily at set times
up to week 24, but from week 24 to 52, patients recorded the mid-
point for basal and bolus insulin dose for each week, therefore,
comparing changes in the insulin dose over these periods was not
possible. Furthermore, CGM devices were worn only prior to the
week 24 visit, but not the week 52 visit; therefore, long-term CGM
outcomes were not available. The absence of a protocol-mandated
insulin titration algorithm, while more closely reflecting real-world
clinical practice and management, may have masked the full
glycaemic potential of dapagliflozin. On the other hand, the LOCF
method, used for imputing missing data, may have led to an over-
estimation of the effect size. Another limitation could be the
absence of information on diet, including carbohydrate intake, dur-
ing these studies. Finally, the monitoring of DKA and
hypoglycaemia in real-world situations may differ from that con-
ducted in a randomized controlled trial setting, which includes care-
fully selected patients.
In conclusion, this pooled analysis of a large, geographically
diverse population of patients with T1D showed that dapagliflozin
was well tolerated and led to clinically relevant improvements in
glycaemic control and weight reduction, without an increased risk of
severe hypoglycaemia. Compared with placebo, the risk of DKA was
higher in patients treated with dapagliflozin; however, this risk may be
mitigated by appropriate patient selection, education and other risk-
mitigation strategies when treating adults with T1D with adjunct
dapagliflozin therapy.
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